New Phase 3 trial: Phase 3 Randomized Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation — Eledon Pharmaceuticals
Why now
Thesis: Eledon Phase 3 transplant trial registration, binary pipeline event
Catalyst to watch: Trial enrollment and data readout
Main risk: Failure versus established tacrolimus
Why it matters
Tegoprubart vs tacrolimus transplant trial is pipeline news for Eledon, a small listed biotech.
Details
Sponsor: Eledon Pharmaceuticals; Status: Not Yet Recruiting; Conditions: Kidney Transplant Rejection; Interventions: Tegoprubart, Tacrolimus; Enrollment: 620 (estimated); First posted: 2026-09-23; NCT: NCT07835581
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-23 12:00 UTC